United Therapeutics Corporation $UTHR Shares Purchased by F m Investments LLC

F m Investments LLC boosted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 38.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,600 shares of the biotechnology company’s stock after acquiring an additional 2,126 shares during the quarter. F m Investments LLC’s holdings in United Therapeutics were worth $3,703,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Ethic Inc. boosted its stake in United Therapeutics by 9.5% during the fourth quarter. Ethic Inc. now owns 956 shares of the biotechnology company’s stock worth $466,000 after buying an additional 83 shares during the period. Ballentine Partners LLC boosted its stake in United Therapeutics by 10.2% during the fourth quarter. Ballentine Partners LLC now owns 549 shares of the biotechnology company’s stock worth $268,000 after buying an additional 51 shares during the period. Allegiance Financial Group Advisory Services LLC purchased a new position in United Therapeutics during the fourth quarter worth about $270,000. Sequoia Financial Advisors LLC boosted its stake in United Therapeutics by 83.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 3,271 shares of the biotechnology company’s stock worth $1,594,000 after buying an additional 1,487 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in United Therapeutics by 29.3% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,062 shares of the biotechnology company’s stock worth $2,466,000 after buying an additional 1,146 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on United Therapeutics’ pipeline and growth catalysts, especially encouraging Tyvaso data in IPF and optimism around ralinepag’s blockbuster potential, which could support future revenue growth. UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
• Positive Sentiment: Royal Bank of Canada kept an outperform rating and only slightly lowered its price target to $701 from $707, signaling continued confidence in upside from current levels. RBC lowers price target on UTHR
• Neutral Sentiment: United Therapeutics held its Q1 2026 earnings call, which investors are likely parsing for commentary on Tyvaso, ralinepag, and the company’s growth outlook. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 results missed estimates, with EPS of $5.82 versus expectations of $7.00 and revenue of $781.5 million versus $797.4 million expected; revenue also declined 1.6% year over year. Q1 2026 Financial Results
• Negative Sentiment: Insider selling may be weighing on sentiment: CEO Martine Rothblatt sold 9,500 shares and EVP Paul Mahon sold 8,300 shares, both sizable reductions in their holdings. Rothblatt SEC filing Mahon SEC filing

Analyst Upgrades and Downgrades

Several research analysts have weighed in on UTHR shares. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday. TD Cowen increased their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Finally, UBS Group increased their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. The SEC filing for this sale provides additional information. In the last three months, insiders sold 485,155 shares of company stock valued at $266,370,949. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $564.94 on Friday. The firm has a 50 day simple moving average of $550.17 and a 200-day simple moving average of $501.37. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap of $23.98 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.77 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the business posted $6.63 EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 27.4 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.